NuCana (NCNA) Accumulated Expenses (2016 - 2025)

NuCana (NCNA) reported Accumulated Expenses of $5.5 million for Q4 2025, down 24.69% on a YoY basis from $7.3 million in Q4 2024, and down 7.36% sequentially from $6.0 million in Q3 2025.

NuCana (NCNA) Accumulated Expenses (2016 - 2025) Analysis & Trends

NuCana (NCNA) has 10 years of Accumulated Expenses data on file, last reported at $5.5 million in Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 24.69% year-over-year to $5.5 million; the trailing twelve-month figure through Dec 2025 stood at $5.5 million (down 24.69% YoY), and the FY2025 full-year result was $5.5 million, down 25.05% from the prior year.
  • Accumulated Expenses slipped to $5.5 million in Q4 2025, from $6.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $12.8 million in Q4 2021 to a low of $5.5 million in Q4 2025.
  • A 5-year average of $9.1 million and a median of $9.1 million in 2022 frame the typical range for Accumulated Expenses.
  • Across the five-year window, Accumulated Expenses soared 84.73% in 2021 and sank 48.19% in 2025, its largest moves.
  • Tracing NCNA's Accumulated Expenses over 5 years: stood at $12.8 million in 2021, then decreased by 8.49% to $11.7 million in 2022, then slipped by 5.42% to $11.1 million in 2023, then slumped by 33.9% to $7.3 million in 2024, then retreated by 24.69% to $5.5 million in 2025.
  • Business Quant data shows NCNA's Accumulated Expenses at $5.5 million in Q4 2025, $6.0 million in Q3 2025, and $6.3 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 5.52 Mn
Sep 30, 2025 5.96 Mn
Jun 30, 2025 6.32 Mn
Mar 31, 2025 5.83 Mn
Dec 31, 2024 7.33 Mn
Sep 30, 2024 11.31 Mn
Jun 30, 2024 12.19 Mn
Mar 31, 2024 10.52 Mn
Dec 31, 2023 11.10 Mn
Sep 30, 2023 8.04 Mn
Jun 30, 2023 6.74 Mn
Mar 31, 2023 7.81 Mn
Dec 31, 2022 11.73 Mn
Sep 30, 2022 11.14 Mn
Jun 30, 2022 10.08 Mn
Mar 31, 2022 12.00 Mn
Dec 31, 2021 12.82 Mn
Sep 30, 2021 10.77 Mn
Jun 30, 2021 7.99 Mn
Mar 31, 2021 7.01 Mn